New hope for tough pancreatic cancer? experimental combo enters human testing
NCT ID NCT03301805
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests an experimental oral liquid called BLEX 404 combined with standard chemotherapy (gemcitabine) in 40 people with advanced pancreatic cancer that cannot be removed by surgery or has spread. The study first finds a safe dose, then checks if the combo shrinks tumors or slows the disease. It is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BLEX 404 oral liquid combined with gemcitabine chemotherapy
- What this could lead to
- If successful, this could point toward a new combination treatment that helps control advanced pancreatic cancer for a time.
- What could go wrong
- This is an early phase 2 trial with only 40 people, so results may not apply broadly. The drug combo may cause serious side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED INOPERABLE OR METASTATIC PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a vaccine help fight Hard-to-Treat cancers?
- Blood and gut clues may flag pancreatic cancer risk early
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- MRI might reveal hidden pancreatic risks in obesity
- Can a new PET tracer light up hidden cancers?
- Can a pill rouse the immune system against pancreatic cancer?